Excess total mortality in 2021 in Italy was about one third of that observed in 2020.


Journal

La Medicina del lavoro
ISSN: 0025-7818
Titre abrégé: Med Lav
Pays: Italy
ID NLM: 0401176

Informations de publication

Date de publication:
23 Dec 2021
Historique:
received: 21 11 2021
accepted: 29 11 2021
entrez: 23 12 2021
pubmed: 24 12 2021
medline: 25 12 2021
Statut: epublish

Résumé

Italy was severely hit by the Covid-19 pandemic with an excess of around 90,000 total deaths in 2020. Comparable data in 2021 are needed for monitoring the effects of the interventions adopted to control its spread and reduce the burden. This study estimates the excess mortality in Italy in the first eight months of 2021, with a focus on the working age population. Excess mortality was estimated as difference between the number of registered deaths and the expected deaths. Expected deaths in March-December 2020 and January-August 2021 were estimated separately by sex, through an over-dispersed Poisson regression model using mortality and population data for the period 2011-2019 (before the Covid-19 outbreak). The models included terms for calendar year, age group, a smooth function of week of the year and the natural logarithm of the population as offset term.  Results: In the first eight months of 2021, we estimated 34,599 excess deaths (+7.9% of the expected deaths), of these 3667 were among individuals of working age (25-64 years). In this age group, mortality was 8.2% higher than expected with higher excesses among men (2972 deaths, +10.7%) than women (695 deaths, +4.1%). The excess deaths in the first eight months of 2021 account for about one third of that registered in 2020. Current data indicate that around 5000 excess deaths are expected by the end of the year, leading to a total excess for 2021 of around 40 thousand deaths. Despite the absence of influenza in January-March 2021, a relevant excess was also observed among the working age population.

Sections du résumé

BACKGROUND BACKGROUND
Italy was severely hit by the Covid-19 pandemic with an excess of around 90,000 total deaths in 2020. Comparable data in 2021 are needed for monitoring the effects of the interventions adopted to control its spread and reduce the burden. This study estimates the excess mortality in Italy in the first eight months of 2021, with a focus on the working age population.
METHODS METHODS
Excess mortality was estimated as difference between the number of registered deaths and the expected deaths. Expected deaths in March-December 2020 and January-August 2021 were estimated separately by sex, through an over-dispersed Poisson regression model using mortality and population data for the period 2011-2019 (before the Covid-19 outbreak). The models included terms for calendar year, age group, a smooth function of week of the year and the natural logarithm of the population as offset term.  Results: In the first eight months of 2021, we estimated 34,599 excess deaths (+7.9% of the expected deaths), of these 3667 were among individuals of working age (25-64 years). In this age group, mortality was 8.2% higher than expected with higher excesses among men (2972 deaths, +10.7%) than women (695 deaths, +4.1%).
CONCLUSIONS CONCLUSIONS
The excess deaths in the first eight months of 2021 account for about one third of that registered in 2020. Current data indicate that around 5000 excess deaths are expected by the end of the year, leading to a total excess for 2021 of around 40 thousand deaths. Despite the absence of influenza in January-March 2021, a relevant excess was also observed among the working age population.

Identifiants

pubmed: 34939614
doi: 10.23749/mdl.v112i6.12601
pmc: PMC8759051
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

414-421

Références

Panminerva Med. 2021 Jan 25;:
pubmed: 33494569
Med Lav. 2020 Oct 31;111(5):351-353
pubmed: 33124605
Int J Epidemiol. 2021 Jan 23;49(6):1909-1917
pubmed: 33053172
Eur J Epidemiol. 2021 Feb;36(2):213-218
pubmed: 33495860
BMJ. 2021 May 19;373:n1137
pubmed: 34011491
Panminerva Med. 2021 Apr 28;:
pubmed: 33908730
N Engl J Med. 2020 May 21;382(21):e71
pubmed: 32369276
Front Public Health. 2021 Jul 16;9:669209
pubmed: 34336767
PLoS One. 2021 Jun 4;16(6):e0252454
pubmed: 34086762
Lancet. 2020 Sep 12;396(10253):e27-e28
pubmed: 32891216
PLoS One. 2020 Oct 9;15(10):e0240286
pubmed: 33035253

Auteurs

Gianfranco Alicandro (G)

Department of Pathophysiology and Transplantaersità degli Studi di Milano, Cystic Fibrosis Centre, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy. gianfranco.alicandro@unimi.it.

Giuseppe Remuzzi (G)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy. giuseppe.remuzzi@marionegri.it.

Stefano Centanni (S)

Respiratory Unit, Department of Health Sciences, ASST Santi Paolo e Carlo, Università degli Studi di Milano, Mi-lan, Italy. stefano.centanni@unimi.it.

Alberto Gerli (A)

Respiratory Unit, Department of Health Sciences, ASST Santi Paolo e Carlo, Università degli Studi di Milano, Mi-lan, Italy. alberto@albertogerli.it.

Carlo La Vecchia (C)

Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy. carlo.lavecchia@unimi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH